MA Boston의 림프종 임상 시험
림프종 관련 연구 33개가 Boston 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
피험자 모집 중1상
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
피험자 모집 중2상
- Dana-Farber Cancer Institute, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
피험자 모집 중
- Mass General Hospital, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
피험자 모집 중
- Mass General Brigham, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
피험자 모집 중1/2상
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
피험자 모집 중2상
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
피험자 모집 중1/2상
- Research Site, Boston
- Research Site, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
피험자 모집 중1/2상
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
피험자 모집 중3상
- Research Site, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
피험자 모집 중4상
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
피험자 모집 중2상
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
피험자 모집 중2상
- Dana Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
피험자 모집 중1/2상
- Call for Information (Investigational Site 0026), Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
피험자 모집 중1/2상
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
피험자 모집 중관찰 연구
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
피험자 모집 중
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
피험자 모집 중
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
피험자 모집 중1/2상
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
피험자 모집 중
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
피험자 모집 중2상
- Dana-Farber Cancer Institute, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
피험자 모집 중2상
- Beth Israel Deaconess Medical Center, Boston
Odronextamab in Low Tumor Volume Advanced FL
피험자 모집 중2상
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
피험자 모집 중2상
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
피험자 모집 중2상
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
피험자 모집 중2상
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
피험자 모집 중1상
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
피험자 모집 중
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
피험자 모집 중1/2상
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
피험자 모집 중1/2상
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
피험자 모집 중2상
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
피험자 모집 중
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
다른 도시의 림프종 시험
- Houston, TX연구 34개
- New York City, NY연구 33개
- Washington, DC연구 23개
- Baldwin Park, CA연구 21개
- Chicago, IL연구 20개
- Durham, NC연구 17개
- St. Louis, MO연구 15개
- Philadelphia, PA연구 15개
- Cleveland, OH연구 14개
- Edison, NJ연구 12개
- Atlanta, GA연구 12개
- Seattle, WA연구 12개
Boston의 다른 연구
- 유방암연구 111개
- 비소세포폐암연구 90개
- 암 (전체)연구 86개
- 대장직장암연구 63개
- 전이성 암연구 63개
- 폐암연구 62개
- 난소암연구 61개
- 전립선암연구 59개
- 우울증연구 52개
- 자궁내막암연구 50개
- 심부전연구 44개
- 급성 골수성 백혈병연구 44개
ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.